Full-Time
Updated on 8/13/2026
Global medical devices and diagnostics provider
No salary listed
Tempe, AZ, USA
In Person
Master's, MBA, PharmD, PhD, MD
See people who can refer or advise you
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access. July 31 (Reuters) - Becton Dickinson said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users reported difficulty in removing a part of the device after using it on patients. Here are some details: - The product, called an intraosseous needle set, is used to deliver fluids and medicine quickly into a patient's bone when a regular IV line cannot be used fast enough. This is often done in emergencies, such as cardiac arrest or severe trauma. - Becton said the issue involves a part called the obturator, or stylet, which sometimes cannot be removed after the needle is inserted. - The company said this incident can happen if the drill used to insert the needle is not pulled straight back, or if the obturator is rotated the wrong way when taken out. - As of June 2026, BD said it had received 75 complaints and 45 reports of serious injury related to the problem. The company also said four patients died when the part could not be removed during resuscitation efforts for people who had suffered cardiac arrest outside a hospital. - The affected needle sets were made with parts slightly out of the normal size range and were shipped between September 30, 2024, and June 12, 2026. - The recall does not include the intraosseous powered driver, which is the tool used to insert the needles. - BD said that if the obturator cannot be removed, medical staff may need to get a new needle or switch to another way of giving treatment, like a peripheral IV catheter. That delay could be dangerous, especially for critically ill patients, the company said. - The U.S. Food and Drug Administration has been informed about the recall, BD said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch. July 29, 2026 Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. * FRANKLIN LAKES, N.J. and SÃO PAULO - BD (Becton, Dickinson and Company) a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes. Global demand for GLP-1 therapies has highlighted the critical need for delivery systems that enable safe, accurate, and consistent dosing for patients. Many patients face challenges with ease of use, confidence with self-injection and adherence to treatment, making intuitive and reliable delivery solutions increasingly important. EMS's semaglutide utilizes BD's established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra(TM) Injection Pen platform reflects BD's deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies. "BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection." "Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS. "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X or Instagram @becton_dickinson. About EMS EMS is one of Brazil's leading pharmaceutical companies, with more than 60 years of experience developing and delivering innovative, high-quality therapies. The company operates across prescription medicines, generics and OTC, with a growing global footprint spanning more than 60 countries. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies for obesity and type 2 diabetes. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company) Original source here.
BD and EMS have launched a semaglutide therapy in Brazil to expand access to GLP-1 treatments for obesity and type 2 diabetes. The collaboration addresses growing demand for metabolic disease therapies whilst tackling patient challenges with self-injection and treatment adherence. EMS's semaglutide uses BD's Vystra injection pen platform, which features an intuitive design aimed at improving ease of use for patients. The pen platform reflects BD's expertise in drug delivery systems and supports scalable solutions to meet rising demand for injectable therapies. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. EMS operates across more than 60 countries and continues investing in advanced manufacturing and peptide capabilities.